CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients

Journal of Immunology

Volumn 194, Issue 7, 2015, Pages 3475-3486

  Djenidi, Fayҫal ^a,b,c   Adam, Julien ^b,c   Goubar, Aïcha ^b,c   Durgeau, Aurélie ^a,b,c   Meurice, Guillaume ^b,c   De Montpréville, Vincent ^a,d   Validire, Pierre ^e   Besse, Benjamin ^b,c   Mami Chouaib, Fathia ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TIM 3; RECEPTOR; UNCLASSIFIED DRUG; ALPHA E INTEGRINS; ALPHA INTEGRIN; HAVCR2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; NON SMALL CELL LUNG CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; ANTIBODY SPECIFICITY; CYTOTOXICITY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LUNG TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD8; CARCINOMA, NON-SMALL-CELL LUNG; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTEGRIN ALPHA CHAINS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; ORGAN SPECIFICITY; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RISK FACTORS;

EID: 84925852186     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402711     Document Type: Article

References (50)

1. Bossi, G., C. Trambas, S. Booth, R. Clark, J. Stinchcombe, and G. M. Griffiths. 2002. The secretory synapse: the secrets of a serial killer. Immunol. Rev. 189: 152-160.
2. Anikeeva, N., K. Somersalo, T. N. Sims, V. K. Thomas, M. L. Dustin, and Y. Sykulev. 2005. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 102: 6437-6442.
3. 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J. Exp. Med. 204: 559-570.
4. Kilshaw, P. J., and S. J. Murant. 1990. A new surface antigen on intraepithelial lymphocytes in the intestine. Eur. J. Immunol. 20: 2201-2207.
5. 7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins. J. Immunol. 176: 2161-2172.
6. Annacker, O., J. L. Coombes, V. Malmstrom, H. H. Uhlig, T. Bourne, B. Johansson-Lindbom, W. W. Agace, C. M. Parker, and F. Powrie. 2005. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J. Exp. Med. 202: 1051-1061.
7. French, J. J., J. Cresswell, W. K. Wong, K. Seymour, R. M. Charnley, and J. A. Kirby. 2002. T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy? Br. J. Cancer 87: 1034-1041.
8. + intraepithelial lymphocytes - a unique population in microsatellite unstable sporadic colorectal cancer. Eur. J. Cancer 39: 469-475.
9. 7 integrin) in high-grade serous ovarian cancer. Gynecol. Oncol. 118: 228-236.
10. Webb, J. R., K. Milne, P. Watson, R. J. Deleeuw, and B. H. Nelson. 2014. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20: 434-444.
11. Mokrani, M., J. Klibi, D. Bluteau, G. Bismuth, and F. Mami-Chouaib. 2014. Smad and NFAT pathways cooperate to induce CD103 expression in human CD8 T lymphocytes. J. Immunol. 192: 2471-2479.
12. Franciszkiewicz, K., A. Le Floc'h, M. Boutet, I. Vergnon, A. Schmitt, and F. Mami-Chouaib. 2013. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res. 73: 617-628.
13. Le Floc'h, A., A. Jalil, K. Franciszkiewicz, P. Validire, I. Vergnon, and F. Mami-Chouaib. 2011. Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cγ-dependent pathway. Cancer Res. 71: 328-338.
14. Turner, D. L., C. L. Gordon, and D. L. Farber. 2014. Tissue-resident T cells, in situ immunity and transplantation. Immunol. Rev. 258: 150-166.
15. + T cells. J. Exp. Med. 196: 877-886.
16. + T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J. Exp. Med. 201: 1647-1657.
17. Zhang, N., and M. J. Bevan. 2013. Transforming growth factor-β signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. Immunity 39: 687-696.
18. + tissue-resident memory T cells of skin. Nat. Immunol. 14: 1294-1301.
19. Wakim, L. M., A. Woodward-Davis, R. Liu, Y. Hu, J. Villadangos, G. Smyth, and M. J. Bevan. 2012. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J. Immunol. 189: 3462-3471.
20. Masopust, D., D. Choo, V. Vezys, E. J. Wherry, J. Duraiswamy, R. Akondy, J. Wang, K. A. Casey, D. L. Barber, K. S. Kawamura, et al. 2010. Dynamic T cell migration program provides resident memory within intestinal epithelium. J. Exp. Med. 207: 553-564.
21. Wakim, L. M., A. Woodward-Davis, and M. J. Bevan. 2010. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc. Natl. Acad. Sci. USA 107: 17872-17879.
22. Gebhardt, T., and F. R. Carbone. 2009. Immunology: a helpers' guide to infection. Nature 462: 418-419.
23. RM cells providing global skin immunity. Nature 483: 227-231.
24. + T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J. Clin. Invest. 121: 2254-2263.
25. RM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. USA 109: 7037-7042.
26. Cyster, J. G., and S. R. Schwab. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30: 69-94.
27. Cauley, L. S., and L. Lefranc¸ois. 2013. Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells. Mucosal Immunol. 6: 14-23.
28. + T cells. Nat. Immunol. 14: 1285-1293.
29. Franciszkiewicz, K., A. Le Floc'h, A. Jalil, F. Vigant, T. Robert, I. Vergnon, A. Mackiewicz, K. Benihoud, P. Validire, S. Chouaib, et al. 2009. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res. 69: 6249-6255.
30. 6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328.
31. v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19: 1617-1624.
32. 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. J. Immunol. 175: 4355-4362.
33. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124: 2246-2259.
34. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252-264.
35. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
36. Freeman, G. J., E. J. Wherry, R. Ahmed, and A. H. Sharpe. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203: 2223-2227.
37. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8: 1246-1254.
38. Blackburn, S. D., H. Shin, G. J. Freeman, and E. J. Wherry. 2008. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc. Natl. Acad. Sci. USA 105: 15016-15021.
39. + T cell dysfunction in melanoma patients. J. Exp. Med. 207: 2175-2186.
40. Jones, R. B., L. C. Ndhlovu, J. D. Barbour, P. M. Sheth, A. R. Jha, B. R. Long, J. C. Wong, M. Satkunarajah, M. Schweneker, J. M. Chapman, et al. 2008. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205: 2763-2779.
41. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207: 2187-2194.
42. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8: 793-800.
43. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
44. Champiat, S., E. Ileana, G. Giaccone, B. Besse, G. Mountzios, A. Eggermont, and J. C. Soria. 2014. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J. Thorac. Oncol. 9: 144-153.
45. Mulé, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel, S. A. Rosenberg, and T. J. Schall. 1996. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7: 1545-1553.
46. Uekusa, Y., W. G. Yu, T. Mukai, P. Gao, N. Yamaguchi, M. Murai, K. Matsushima, S. Obika, T. Imanishi, Y. Higashibata, et al. 2002. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res. 62: 3751-3758.
47. Jöhrer, K., L. Pleyer, A. Olivier, E. Maizner, C. Zelle-Rieser, and R. Greil. 2008. Tumour-immune cell interactions modulated by chemokines. Expert Opin. Biol. Ther. 8: 269-290.
48. + T-cell infiltration. Int. J. Colorectal Dis. 25: 417-424.
49. Mañes, S., E. Mira, R. Colomer, S. Montero, L. M. Real, C. Gómez-Moutón, S. Jiménez-Baranda, A. Garzón, R. A. Lacalle, K. Harshman, et al. 2003. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J. Exp. Med. 198: 1381-1389.
50. Ugurel, S., D. Schrama, G. Keller, D. Schadendorf, E. B. Bröcker, R. Houben, M. Zapatka, W. Fink, H. L. Kaufman, and J. C. Becker. 2008. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol. Immunother. 57: 685-691.